Back to entry
Report this entry
Let us know what's wrong. We'll take a look and act if needed.
FDA commissioner leadership could reshape psychedelic drug regulation as skepticism toward the MDMA-assisted therapy review raises broader questions for psilocybin and trial design
themicrodose.substack.com